SecBot SecBot
SECBOTREPLAY Home › Report › RARE

RARE · Ultragenyx reported Q2 2026 revenue of $214M (beat $183.1M consensus by…

Ultragenyx Pharmaceutical Inc. · 8-K filed Aug 4, 2026 at 16:09 ET

At the news

BULLISHIMPACT 6/10

8-K filed Aug 4, 2026 at 16:09 ET

Ultragenyx reported Q2 2026 revenue of $214M (beat $183.1M consensus by 17%, +28% YoY) and EPS of -$0.90 (beat -$1.00 consensus by 10%, narrowed from -$1.17 YoY). All products showed strong growth, full-year 2026 guidance was reaffirmed, and management reiterated its path to profitability in 2027. The company highlighted upcoming H2 catalysts: two PDUFA dates (DTX401 gene therapy Aug 23, UX111 gene therapy Sep 19) and GTX-102 Phase 3 Angelman data in Sep/Oct.

  • Q2 2026 total revenue $214M, up 28% YoY from $167M
  • EPS -$0.90 vs consensus -$1.00 (10% beat) and vs -$1.17 YoY
  • Crysvita revenue $156M (+29% YoY), Dojolvi $27M (+17%), Evkeeza $21M (+50%), Mepsevii $10M (+11%)
  • Net loss narrowed to $92M from $115M YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access